AKR1B10 and lung carcinoma: A number of AKR1B10 inhibitors have been developed, of which HCCFA, the most potent, significantly inhibits not only the migration, proliferation, and metastasis of lung cancer A549 cells, but also the metastatic and invasive abilities of cisplatin-resistant A549 cells.